Genetic research solves 30-year leukemia mystery

Share This Post

Researchers at the University of California, San Francisco and St. Jude Children ’s Research Hospital in Tennessee have solved medical mysteries decades ago, and they have discovered a pair of genetic mutations that may cause familial blood diseases and even leukemia. This study is based on DNA analysis of 16 siblings in 5 families, pointing out that some children with inherited mutations will recover on their own, and also found some other genetic markers that help doctors avoid invasive and dangerous bone marrow transplants.

The problems surrounding this disease can be traced back more than 30 years ago, when the oncologist Kevin Shannon, MD, of the University of California, San Francisco, and colleagues met several families, many of whom may have low blood cell counts (abnormal myelodysplastic syndrome) Sign or MDS) and an acute myeloid leukemia (AML), a severe and fatal blood cancer. These patients have one instead of the usual two copies of chromosome 7, which is called single chromosome 7.

The data shows that mutations in the genes SAMD9 and SAMD9L located on chromosome 7 are closely related to single chromosome 7 syndrome, but many healthy siblings and patients’ parents also carry these mutations without any symptoms. Researchers have shown that patients who do have symptoms of MDS and AML also have a specific secondary gene mutation, which can drive a more serious disease, and patients without these additional mutations often never experience any symptoms and may develop blood. The count is low but most can recover on their own without treatment.

Genetic changes on chromosome 7 are very frequent in patients with AML and MDS, and malignant tumors of single chromosome 7 are associated with poor prognosis and do not respond well to existing therapies. With more than 860 genes on chromosome 7, it will be interesting to understand the role of SAMD9 and SAMD99L in non-familial MDS and AML and how they interact with other genes on chromosome 7.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy